KalGene: the asset was a licence, and the NRC took it back

KalGene Inc. was incorporated under the Canada Business Corporations Act on December 21, 2006 and operated from Royalmount Avenue in Montreal.

It was "a venture-backed, private entity engaged in pre-clinical life sciences and biotechnology research and development relating to therapies for Alzheimer's disease", per Report on the Trustee's Preliminary Administration, May 19, 2026, paras. 6–7.

It filed an assignment in bankruptcy on April 29, 2026, per Certificate of appointment, April 29, 2026.

What it owned

The company's drug candidate was known as KG207. The technology behind it was licensed from the National Research Council of Canada, under a licensing agreement for its development and potential commercialisation, per Report on the Trustee's Preliminary Administration, May 19, 2026, para. 8.

That single sentence is the whole balance sheet of a company like this. A pre-clinical biotech has no revenue, no plant worth anything and no inventory. What it has is the right to develop a molecule, and the accumulated work — manufacturing optimisation, toxicology studies, preparation of regulatory filings — done under that right, per Report on the Trustee's Preliminary Administration, May 19, 2026, para. 15.

The work has value only so long as the right survives.

Who paid for it

The financing history is worth setting out because it identifies who lost the money, per Report on the Trustee's Preliminary Administration, May 19, 2026, paras. 9–10.

KalGene financed its operations through grants, equity investments and debt financing, including convertible debentures and convertible promissory notes. Its investors and debt holders included individual investors, venture capital investors, and philanthropic organizations with interests in the neuroscience and life sciences sector.

And it kept trying. It pursued financing and strategic transaction opportunities with crossover investors, venture capital groups, family offices, pharmaceutical companies, and through a proposed special purpose acquisition company transaction.

The SPAC "was not completed after the Debtor was unable to raise the required financing". Efforts to secure grant funding, pharmaceutical partnerships and private investment likewise produced nothing.

The philanthropic money is the part that will stay with readers. Some of the $22.6 million now unrecoverable was given by organisations whose purpose is funding Alzheimer's research — money that was never expected to earn a return, but was expected to buy a drug.

The market closed first

The company's own explanation, from its stakeholder update of March 18, 2025, is quoted in the report: financing conditions for pre-clinical biotechnology companies had become increasingly difficult, including reduced venture capital activity, limited access to public capital markets, and reduced investor appetite for early-stage neuroscience opportunities, per Report on the Trustee's Preliminary Administration, May 19, 2026, para. 11.

That is an accurate description of the sector in that period, and it is also the specific problem with early-stage neuroscience. Alzheimer's drug development has one of the highest failure rates in medicine and one of the longest paths to revenue. When capital tightens, it is the first thing investors stop funding — not because any particular candidate is worse, but because the time to an answer is longest.

The licence

Then the event that ended it:

On or about January 9, 2025, the NRC terminated the licence relating to the KG207 technology, which impacted the Debtor's ability to continue operations.

Per Report on the Trustee's Preliminary Administration, May 19, 2026, para. 12.